16.9 C
New York
Thursday, May 19, 2022

Proposed Public Offering: Statera Biopharma, Inc. (STAB) Stock Descends Further After Hours.

Statera Biopharma, Inc. (STAB) is a biotherapeutics company engaged in the production of novel immunotherapeutics to treat various diseases as its toll-like receptor is an important part of the innate immune system. Its clinical products platform includes STAT-201 for treating Crohn’s disease, STAT-401 used for pancreatic carcinoma, Entolimod used for hematological disorders, and STAT-205 used for COVID-19.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


STAB stock price on March 21, 2022, regular trading session, dropped by 7.20% to be $0.59. Its price plummeted deep as of the writing in the aftermarket session by 27.6%.

STAB: Events and Happenings

On March 21, 2022, STAB announced the commencement of an underwritten public offering. The offering of the entities consists of one common stock share and one warrant to acquire one common stock share. While the pre-funded entities consist of one pre-funded warrant to acquire one common stock share and one warrant to acquire one common stock share. The company is offering regarding a ‘shelf’ registration statement on Form S-3 filed with the SEC with effect from May 29, 2020.

On March 08, 2022, STAB stated its revised preliminary financial outcomes for the fiscal year 2021, which ended December 31, 2021. During the year, the revenues of the company were noted to be $1.48 million and observed an increase of 100% versus FY 2020.

STAB: Key Financial

STAB released its consolidated financial results on November 15, 2021, for the third quarter of 2021 ended September 30, 2021. Some key aspects are discussed here.


Revenues during the third quarter of fiscal 2021 were recorded to be $0.23 million versus no revenue in Q3 2020. It observed a 100% gain in its YoY revenue.


Net loss per share (basic and diluted) in Q3 2021 was $12.7 million or $0.47 as compared to $5.7 million or $1.84 during the same quarter of 2020. The company’s EPS inclined YoY.


STAB stock dipped by approximately 90% in the last year as an outcome of the economic restrictions imposed in the pandemic. The current immediate drop in stock price is likely associated with the company’s announcement of the proposed underwritten public offering.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles